Talia Cohen Solal is the CEO and co-founder of Genetika+ where they are developing new tools to guide therapy for Major Depressive Disorder. Talia Cohen Solal is a Neuroscientist who received her BA/MA in Neuroscience from University of Oxford, a PhD from University College London working on the underlying mechanisms of schizophrenia of and then completed her fellowship at Columbia University developing translational tools for mental illness. She moved on to work in the Biotech Sector in operations, project management and scientific strategy in addition to advising other start-ups in their work.  Dr Cohen Solal has through her academic career raised funds in 8 grants totaling $1.5 Million in funding, published 10 academic papers and filed 3 patents all in the field of Neuroscience.